Q3 Revenue Drops 61.4% to $449.1K as Dyadic Flags Going-Concern Doubt
DYAI is trading near its 52-week low of $0.33 (6.1% above the low).
Summary
Q3 revenue collapsed 61.4% to $449.1K from $1.2M a year ago as grant and R&D revenue dried up; first direct product sales were immaterial. The net loss narrowed to $1.4M from $2.0M, but that was helped by a $545.5K non-cash warrant-liability gain, not operations. Cash, restricted cash and securities fell to $6.0M from $8.6M at December 31, 2025, and the company again disclosed substantial doubt about continuing as a going concern for 12 months. This lands on top of the September 25 Nasdaq deficiency notices for the $1 minimum bid price and another listing standard, with the stock at $0.35 and an already-active at-the-market program. Only $225K of expected Q4 milestone revenue from a partner's second chymosin commercial sale is on the near-term horizon; comparative preclinical study results are anticipated in Q1 2027.
At the time of this announcement, DYAI was trading at $0.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14M. The 52-week trading range was $0.33 to $1.60. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.